QUARTER HORSE RACING COMMITTEE MEETING AGENDA Tuesday, April 18, 2017 - 9:00am Charleston Marriott, Charleston, SC, USA
1. Call to Order 2. AQHA Report - Janet VanBebber 3. Clenbuterol regulation: (Discussion and Possible Action Item) A) Discrepancy between ARCI Controlled Therapeutic Schedule threshold for clenbuterol and AQHA desire for total prohibition in and out of competition. B) Breed specific Clenbuterol rules. C) Comments from Texas Racing Commission staff. D) Regulatory Attorney Feedback. E) Private restrictions by tracks, enforced by pre-race exams. 4. Commissioner Lucas letter pertaining to drug regulation in horses prior to commencement of their racing career. 5. Proposed chapters of Model Rules pertaining to Quarter Horse Racing: A) Are they necessary? B) Consideration of comments received. 6. Other Items.
TEXAS RACING COMMISSION INPUT From: Subject: Date: To: Cc:
Chuck Trout
[email protected] RE: Working document to create Quarter Horse Racing specific model rules February 9, 2017 at 5:54 PM Ed Martin
[email protected] Joel Speight
[email protected], Mark Fenner
[email protected], Devon Bijansky
[email protected]
Ed, My staff and I have discussed the proposal to create separate sets of racing rules for Thoroughbreds and Quarter Horses. We believe that having two sets of rules that are largely duplicative, but that have isolated differences between them, will cause confusion among the horsemen and increase the perception that regulators are placing unnecessary regulatory burdens on the industry. Maintaining two duplicative sets of rules will also increase each state agency’s administrative burden without any real benefit. I recommend simply amending the existing rules to incorporate the following Quarter Horse-specific changes: ARCI 008-030 -- A. Jockeys – There are no apprentice jockeys in Quarter Horse racing ARCI 008-015 -- F. Transfer of Ownership – Quarter Horse transfers go through AQHA ARCI 010-030 -- Horses Ineligible (27) – Quarter Horse racing plates (shoes can be 4 millimeters vs. 2 millimeters for Thoroughbreds) Also, treating therapeutic medications differently for Thoroughbreds and Quarter Horses without a scientific or other rational basis for doing so will produce inconsistent outcomes that are difficult to justify and could jeopardize our cases on appeal. The ARCI thresholds, including the one for clenbuterol, should apply to all breeds; if ARCI subsequently decides to eliminate the clenbuterol threshold, it should similarly do so for all breeds. If you have any questions concerning my response, please do not hesitate to give me a call.
Chuck
Chuck Trout Executive Director Texas Racing Commission
Submit Spam
From: Subject: Date: To: Cc:
DAN FICK INPUT
Dan Fick
[email protected] RE: Working document to create Quarter Horse Racing specific model rules January 30, 2017 at 10:06 AM Ed Martin
[email protected] Janet VanBebber
[email protected]
Ed: I appreciate what you are proposing for the AQHA to have a Quarter Horse racing specific section of the ARCI Model Rules similar to what we have with Harness and Greyhound. However, I do not think this is necessary as the majority of the flat racing rules apply to all flat racing breeds – TB, QH, Paint, Arabian, Appaloosa and even mules. When there is a different protocol for Quarter Horses which requires a separate rule such as time trials, straightaway races, ownership transfers, official distances, standing start timing, etc. these rules have been added to the ARCI Flat Racing Rules with a caveat like “In Quarter Horse racing…”. Here are some examples:
ARCI-005-010 Terms (8)Breeder means the owner of the horse's dam at the time of foaling for Thoroughbreds. For Quarter Horses, Appaloosas, Arabians and Paint Horses, the breeder is the owner of the dam at the time of service. ARCI-006-055 Timer/Clocker A.(4)At a racetrack equipped with an appropriate infield totalisator board, the timer shall post the quarter times (splits) for thoroughbred races in fractions as a race is being run. For quarter horse races, the timer shall post the official times in hundredths of a second. ARCI-008-030 Apprentice Jockeys B.(2) The conditions of an apprentice jockey license do not apply to quarter horse racing. A jockey's performances in quarter horse racing do not apply to the conditions of an apprentice jockey license. ARCI-010-020D. Scale of Weights (3) Quarter Horses, Appaloosas and Paints minimum scale weights shall be 120 pounds for two-year-olds, 122 pounds for three-year-olds, and 124 pounds for four-year-olds and older. ARCI-010-035E.(3) Post to Finish (d) In a straightaway race, every horse must maintain position as nearly as possible in the lane in which it starts. If a horse is ridden, drifts or swerves out of its lane in such a manner that it interferes with, impedes or intimidates another horse, it is a foul and may result in the disqualification of the offending horse. ARCI-010-035E.(13) Time Trials In absence of specific conditions for a particular race that set forth criteria to address the situations that may arise from the running of time trials to determine the eligible horses to participate in finals, these rules shall apply: (There are three pages that follow
horses to participate in finals, these rules shall apply: (There are three pages that follow of rules specific to time trials.) There are numerous other examples where rules that predominately apply to Quarter Horse racing are covered in the ARCI Flat Racing Rules. Therefore, I would suggest that additional rules applicable to Quarter Horse Racing, such as Clenbuterol being a forbidden substance, can be successfully covered in the appropriate sections of the Flat Racing Rules. I am concerned that developing a Quarter Horse specific section, which will be a time consuming and arduous process, could be counter-productive in that the proposed Quarter Horse Racing Section of ARCI Model Rules would then have to be reviewed, published and passed in its entirety in every state that races Quarter Horses. Whereas adopting a Quarter Horse specific rule in the Flat Racing Section would be more efficient and effective requiring less effort on the part of all concerned. The establishing of Clenbuterol as a prohibited substance with a limit of detection threshold would be a good test case for the next ARCI Model Rules Committee meeting on medication issues. If AQHA wants, ROAP’s Model Rules Committee could consider a Quarter Horse specific rule designating Clenbuterol as a prohibited substance at their request, and we could work with RMTC fine-tuning the language. Best Regards, Dan Dan Fick ROAP Accredited Senior Steward 817-845-2917 (c) 817-242-2166 (h)
From: Ed Martin [mailto:
[email protected]] Sent: Saturday, January 28, 2017 1:42 PM To: Janet VanBebber; Debbie Schauf; Kelly Cathey; Chuck Trout; Dan Fick; Ismael Trejo; CHARLES GARDINER III; Rudy Casillas; Tom Sage Cc: Larry Eliason; Eric Smith Subject: Working document to create Quarter Horse Racing specific model rules
Please see the attached file which is a working draft - far from done - to create new Model Rule Chapters for quarter horse racing (this gets us into the breed specific medication rules).
Rule Chapters for quarter horse racing (this gets us into the breed specific medication rules). These chapters current mirror the “flat racing” chapters, applicable to both quarter horse and thoroughbred racing. Please mark up at will. I think the clenbuterol policy needs to be changed by way of a footnote to the CONTROLLED THERAPEUTIC SCHEDULE,(will circulate later) where we would indicate that for quarter horse racing a LOD for clenbuterol would apply and not the published threshold. There are probably other places in the rules where clenbuterol should be articulated as being prohibited. There is no current language with regard to a clean hair test as a condition of entry. That could certainly be a House Rule of the track. When you all get a chance, go over this document and remove any items you think may not be applicable to QH races. Also suggest whatever modifications you think appropriate. This is everyone’s opportunity to specifically propose what changes you want. Once we get them all nailed down, we can start the process. Hope this helps. Ed rack. Submit Spam
COMMISSIONER LUCAS OF OKLAHOMA LETTER.
February 6th, 2017 To: Ed Martin/ARCI Model Rules Committee & Racing Compact Board Members Subject: Response to Jan 28th email requesting comments on possibility of ARCI adopting Quarter Horse “racing criteria”. As many of you know, I'm a Board member of the Oklahoma Horse Racing Commission (OHRC). However, the comments below are my own and do not necessarily reflect the position of the OHRC. Over the past few years, the American Quarter Horse Association (AQHA) and the Oklahoma Quarter Horse Racing Association (OQHRA), have offered various proposals for the OHRC to consider supporting/adopting. Most pertain to use, classification, penalties and testing methods for certain therapeutic substances. Their immediate objective is to eliminate the use of Clenbuterol in racing QH’s. To that end, QH leadership has proposed the OHRC allow racetracks to require owners of QH’s to provide a negative hair test for Clenbuterol, prior to a horse entering its initial race at their meet (along with OHRC pre-race/post race, blood, urine & hair testing). I'm not suggesting QH leadership is right or wrong in their endeavors but the OHRC has not taken formal action on their proposals for various reasons. In a somewhat related matter, the ARCI recently approved amendments to its Out of Competition Testing and "MMV" language. This action followed earlier updates of its Controlled
Therapeutic Medication Schedule and Approved Substance list. Due in part to those revisions, and to further the goal of national uniformity, the OHRC is considering adoption of these sections of ARCI Uniform Model Rules. This action would, in effect, establish a threshold level for Clenbuterol in QH’s. Unfortunately, a lack of uniformity between QH leaderships wishes and current ARCI Guidelines that racing commissions are being encouraged to adopt (or prepare to be ostracized by other racing jurisdictions), has placed some commissions in a challenging position. I'm not suggesting what action the OHRC might take to address these issues in the future but we, and other industry leaders, have consequential decisions to make in 2017. At the ARCI meeting in Seattle, I’d asked the Model Rules Committee if there were any plans to address the concept of "Breed Specific" language being added to their Guidelines - that a racing commission might refer to if it was considering adoption of a breed registrars differing criteria. It appears the anticipated formation of Regional Compacts is how the ARCI hopes to address this subject. If so, a related component should be made a part of these (or any other) deliberations involving the possible merger of a breed registrars "racing criteria" and ARCI Guidelines. The referred component pertains to what substances horses are being administered prior to their training and/or racing careers. Our industry, for all practical purposes, has turned a blind eye to this issue. But the fact is, those who are involved in the development, raising, and/or selling of racing stock (private or public), bear as much responsibility for the future health and
welfare of equine athletes as the racing participants that regulators, registrars and the press remain focused on. The permissive ideology that exists in this sector of our industry cannot continue "as is". For this reason, if a registrar wishes to have their "racing criteria" adopted by a racing jurisdiction and/or the ARCI, it should be contingent upon the registrar implementing similar criteria for its breeding & sales industry participants. The recent push to expand Hair and Out of Competition Testing for horses eligible to race could also be utilized by the AQHA as an administrative tool to eliminate the use of Clenbuterol in quarter horse racing stock. Unless language is included that addresses this matter prior to the ARCI adopting a breed registrars "racing criteria", there will be no incentive for a registrar to change the status quo. Without forceful administration over this sector of the industry, the age old "buyer beware" mentality will continue to live on with little or no effective oversight - while racing regulators will (rightfully) be expected to continue looking for new ways to assure owners, buyers and bettors their investments ARE being protected. Myself and others have voiced concerns about this outdated double standard for several years now. But unfortunately, there's been no meaningful effort by breed registrars to adopt or enforce equal health and welfare principles for that sectors participants. Fortunately, recent developments have presented the ARCI with an opportunity to advance this long needed reform by insisting the AQHA adopt accommodating language before it agrees to incorporate their proposed "racing criteria" in its Model Rules.
Hopefully, the AQHA will take advantage of this opportunity to ensure potential buyers/investors they are sincere in their effort to protect all participants in their industry, while setting an example for other registrars to follow. Your consideration of this matter is appreciated.
Respectfully, Joe Lucas
ARCI Controlled Therapeutic Medication Schedule for Horses - Version 3.2 Revised – December 9, 2016.
Controlled Therapeutic Medication
Acepromazine
Albuterol
Betamethasone
Butorphanol
1
Threshold
10 nanograms per milliliter as 2-(1hydroxyethyl) promazine sulfoxide (HEPS) in urine 1 nanogram per milliliter of urine
10 picograms per milliliter of plasma or serum
300 nanograms per milliliter of total butorphanol in urine or 2 nanograms of free butorphanol per milliliter per milliliter of plasma or serum
Withdrawal Guideline
draft clenbuterol footnotes.
Dosing Specifications
Reference Notes
Note
Single intravenous dose of acepromazine at 0.05 milligrams per kilogram
University of California at Davis project
Applicable analyte is metabolite HEPS
72 hours
720 micrograms total dose intra-nasal only1. Based upon dosing up to 4 times per day
European Horseracing Scientific Liaison Committee Data
See Endnote
7 days
Intra-articular administration of 9 milligrams of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP (American Regent product #0517-0720-01)2
RMTC study
Intra-articular dosing only - applicable analyte is betamethasone in plasma or serum
Journal of Veterinary Pharmacology and Therapeutics doi: 10.1111/j.13652885.2012.01385.x
Applicable analytes are total butorphanol (drug and conjugates) in urine and butorphanol in plasma (the drug itself, not any conjugate)
48 hours
48 hours
Single intravenous dose of butorphanol as Torbugesic® (butorphanol tartrate) at 0.1 milligrams per kilogram
Administration of albuterol by any means other than intra-nasally has a high likelihood in resulting in a positive finding. This specifically includes oral administration. Trainers and veterinarians are cautioned against using oral albuterol 2 Intramuscular administration of betamethasone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.
2
Controlled Therapeutic Medication
Cetirizine
6 nanograms per milliliter of plasma or serum
Cimetidine
400 nanograms per milliliter of plasma or serum
Clenbuterol
140 picograms per milliliter of urine or Level of Detection in plasma or serum3
Dantrolene
Detomidine
3 4
Threshold
100 picograms per milliliter of 5-hydroxydantrolene in plasma or serum
2 nanograms per milliliter of carboxydetomidine in urine or 1 nanogram per milliter of detomidine in blood.
Withdrawal Guideline
48 hours
24 hours
14 days
4
48 hours
48 hours
Dosing Specifications
Reference Notes
Note
0.4 milligrams per kilogram twice daily for 5 doses
Kentucky Equine Drug Research Council/University of California at Davis study
Do not administer ivermectin within 48 hours of a race if the horse has been administered cetirizine.
20 milligrams per kilogram twice daily for 7 doses
Kentucky Equine Drug Research Council/University of California at Davis study
Oral administration of clenbuterol as Ventipulmin® syrup (Boehringer-Ingelheim Vetmedica Inc., NADA 140973) at 0.8 mcg/kg twice a day
University of California at Davis; Boehringer-Ingelheim Vetmedica, Inc.
Oral administration of 500 milligrams of dantrolene as paste (compounding pharmacy) or capsule formulation (Proctor and Gamble)
Journal of Veterinary Pharmacology and Therapeutics 34, 238– 246
5 mg IV (once)
KY EDRC, UC Davis/UF Study.
For Quarter Horses, Level of Detection in urine, plasma or serum. Clenbuterol is a prohibited substance in Quarter Horses and there is no applicable withdrawal guideline.
Applicable analyte is clenbuterol
Dormosedan ™ used in study.
3
Controlled Therapeutic Medication
Dexamethasone
Threshold
5 picograms per milliliter of plasma or serum
Diclofenac
5 nanograms per milliliter of plasma or serum
Dimethyl sulfoxide (DMSO)
10 micrograms per milliliter of plasma or serum
Firocoxib
20 nanograms per milliliter of plasma or serum
Withdrawal Guideline
Dosing Specifications
Reference Notes
Note
72 hours
Intramuscular and intravenous administration of dexamethasone sodium phosphate or oral administration of dexamethasone at 0.05milligrams per kilogram regardless of route
RMTC study
Applicable analyte is dexamethasone in plasma or serum
Five inch ribbon topical application of 1% diclofenac liposomal cream formulation. (Surpass Topical AntiInflammatory Cream, IDEXX Pharmaceuticals)
Veterinary Therapeutics 6: 57-66 (2005)
Applicable analyte is diclofenac in plasma or serum
ARCI model rule
Applicable analyte is DMSO in plasma or serum
48 hours
48 hours
14 days
Intravenous
Oral administration of firocoxib as EQUIOXX oral paste at a daily dose of 0.1 milligram per kilogram for four days
RMTC study
Applicable analyte is firocoxib in plasma or serum
4
Controlled Therapeutic Medication
Furosemide
Withdrawal Guideline
100 nanogram per milliliter of plasma or serum
4 hours
Glycopyrrolate
3 picograms per milliliter plasma or serum
Guaifenesin
12 nanograms per milliliter of plasma or serum
48 hours
Isoflupredone
100 picograms per milliliter of plasma or serum
7 days
Lidocaine
5
Threshold
20 picograms per milliliter of total 30Hlidocaine in plasma or serum
48 hours
72 hours
Dosing Specifications
Reference Notes
Note
ARCI model rule
Must also have urine specific gravity < 1.010 for a violation.
Single intravenous dose of 1 milligram of glycopyrrolate as Glycopyrrolate Injection, USP (American Regent product # 0517-4601-25)
RMTC study; Journal of Veterinary Pharmacology and Therapeutics doi: 10.1111/j.13652885.2011.01272.x
Applicable analyte is glycopyrrolate in plasma or serum
2 grams twice daily for 5 doses
Kentucky Equine Drug Research Council/University of California at Davis study
10 milligrams total dose subcutaneous or 20 milligrams total dose in one articular space
RMTC Study
200 milligrams of lidocaine as its hydrochloride salt administered subcutaneously
European Horseracing Scientific Liaison Committee data; Iowa State University study.
Single Intravenous dose of furosemide up to 500 milligram5
Applies to total major hydroxylated metabolite (i.e., includes conjugates)
ARCI-011-020(F)(2)(d) and ARCI-025-020(F)(2)(d) state that the dose of Furosemide “shall not exceed 500 milligrams nor be less than 150 milligrams”.
5
Controlled Therapeutic Medication
Mepivacaine
Methocarbamol
Methylprednisolone
Omeprazole
6
Threshold
Withdrawal Guideline
Dosing Specifications
Reference Notes
10 nanograms total hydroxymepivacaine per milliliter of urine or above Level of Detection of mepivacaine in plasma or serum
72 hours
Single 0.07 milligrams per kilogram subcutaneous dose of mepivacaine
European Horseracing Scientific Liaison Committee data
48 hours
Single intravenous dose of 15 milligrams per kilogram methocarbamol as Robaxin® or 5 grams orally
See Dosing Specifications
Total dose of methylprednisolone acetate suspension in one articular space.6 The recommended withdrawal for methylprednisolone acetate is a minimum of 21 days at a 100 milligram dose
1 nanogram per milliliter of plasma or serum
100 picograms per milliliter of plasma or serum
omeprazole sulfide 10 nanograms per milliliter of plasma or serum
24 hours
Orally (2.2 grams) once daily for 4 doses
Journal of Veterinary Pharmacology and Therapeutics doi: 10.1111/jvp.12068
Journal of Veterinary Pharmacology and Therapeutics volume 37, Issue 2, pages 125–132, April 2014
Kentucky Equine Drug Research Council/University of California at Davis study
Note
Applicable analyte is methocarbamol in plasma or serum
Applicable analyte is methylprednisolone
GastroGuard™ used in the study
Intramuscular administration of methylprednisolone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period. Please see Dosing Specifications for recommended withdrawal time.
6
Controlled Therapeutic Medication
Prednisolone
Procaine penicillin (administration must be reported to Commission)
Ranitidine
Triamcinolone acetonide
Xylazine
7
Threshold
1 nanogram per milliliter of plasma or serum
25 nanograms per milliliter of plasma or serum
40 nanograms per milliliter of plasma or serum
100 picograms per milliliter of plasma or serum
200 picograms per milliliter of plasma or serum
Withdrawal Guideline
48 hours
Following entry to race
24 hours
7 days
48 hours
Dosing Specifications
Reference Notes
Applicable analyte is prednisolone in plasma or serum
1 milligram per kilogram orally
Intramuscular
8 milligrams per kilogram twice daily for 7 doses
Total dose of 9 milligram in one articular space7
200 milligrams intravenously
Note
RMTC – reference notes online
Mandatory surveillance of horse at owner’s expense 6 hours before racing
Kentucky Equine Drug Research Council/University of California at Davis study
Equine Veterinary Journal, 10.1111/evj.12059 (2013)
University of California at Davis study
Applicable analyte is triamcinolone acetonide in plasma or serum
Applicable analyte is xylazine.
Intramuscular administration of triamcinolone acetonide will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.
7
Non-Steroidal Anti-Inflammatory Drug (NSAID) Rules for Horses§§ Controlled Therapeutic Medication
Flunixin
Ketoprofen
Phenylbutazone
§§
Threshold (Primary)
20 nanogram per milliliter of plasma or serum
2 nanograms per milliliter of plasma or serum
2 micrograms per milliliter of plasma or serum
Withdrawal Guideline
32 hours
24 hours
24 hours
Dosing Specifications
Single intravenous dose of flunixin as Banamine® (flunixin meglumine) at 1.1 milligram per kilogram
Single intravenous dose of ketoprofen as Ketofen® at 2.2 milligrams per kilogram
Single intravenous dose of phenylbutazone at 4.0 milligrams per kilogram
Reference Notes
University of California at Davis/RMTC study
HFL Sport Sciences/ Kentucky Equine Drug and Research Council/RMTC study
ARCI model rule
Threshold (Secondary) Secondary antistacking threshold: 3.0 nanograms per milliliter of plasma or serum (Administration 48 hours prior) Secondary antistacking threshold: 1 nanogram per milliliter of plasma or serum (Administration 48 hours prior) Secondary antistacking threshold: 0.3 micrograms per milliliter of plasma or serum (Administration 48-hours prior)
Samples collected may contain one of the NSAIDs in this chart at a concentration up to the Primary Threshold. Samples may also contain another of the NSAIDs in this chart up at a concentration up to the Secondary Threshold. No more than 2 of the NSAIDs in this chart may be present in any sample.
8
Recent Document Revisions Date
Version
Revision
Revision Description
Dec-16
3.2
Omeprazole
Clarified threshold for omeprazole sulfide.
Sep-16
3.1
Detomidine
Amended threshold and dosing specifications.
Mar-16
3
Omeprazole
Amended threshold and dosing specifications
Mar-16
3
Xylazine
Amended threshold and dosing specifications
Mar-16
3
Guaifenesin
Added as New Substance to Controlled Therapeutic Medication Schedule
Mar-16
3
Cetirizine
Added as New Substance to Controlled Therapeutic Medication Schedule
Mar-16
3
Ranitidine
Added as New Substance to Controlled Therapeutic Medication Schedule
Mar-16
3
Cimetidine
Added as New Substance to Controlled Therapeutic Medication Schedule
Apr-15
2.02
Methylprednisolone
Directed readers to use Dosing Specification column for recommended withdrawal guideline.
Apr-15
2.02
Furosemide
Added clarifying language to Furosemide reflecting ARCI-011020(F)(2)(d) and ARCI-025-020(F)(2)(d) minimum and maximum thresholds
Apr-15
2.02
Added “For Horses” to Title
Added the words “for Horses” to document title
Apr-14
2.01
Methocarbamol
Corrected dosage from 0.15 milligrams per kilogram to 15 milligrams per kilogram
Apr-14
2
Dimethyl sulfoxide (DMSO)
Removed “oral” from dosing specifications
Apr-14
2
Xylazine
Changed Note section from “Applies to xylazine and xylazine metabolite” to “Applies to analyte xylazine”
9
Apr-14
2
Xylazine
Corrected typographical error in Threshold from “0.01ng/mg of plasma or serum” to “0.01 nanogram per milliliter of plasma or serum”
Apr-14
2
Isoflupredone
Added Isoflupredone as New Substance to Controlled Therapeutic Medication Schedule
Apr-14
2
Albuterol
Added Albuterol as New Substance to Controlled Therapeutic Medication Schedule
Apr-14
2
Flunixin, Ketoprofen, Phenylbutazone
Added Secondary Anti-Stacking Threshold
Apr-14
2
Flunixin, Ketoprofen, Phenylbutazone
Created separate section for Non-Steroidal Anti-Inflammatory Drugs at end of Controlled Therapeutic Medication Schedule, Relocated Flunixin, Ketoprofen, and Phenylbutazone to new section
Apr-14
2
Changed Table Header from “No Pre-Race Treatment Within” to “Withdrawal Guideline”
Apr-13
1
Original Controlled Therapeutic Medication Schedule Adopted by ARCI Board of Directors
